{"id":18578,"date":"2021-03-31T11:05:15","date_gmt":"2021-03-31T09:05:15","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=18578"},"modified":"2021-06-17T13:05:23","modified_gmt":"2021-06-17T11:05:23","slug":"bioinvent-completes-equity-financing-of-app-eur-157-million-over-a-period-of-less-than-one-year","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/bioinvent-completes-equity-financing-of-app-eur-157-million-over-a-period-of-less-than-one-year\/","title":{"rendered":"BioInvent completes equity financing of app. EUR 157 million over a period of less than one year"},"content":{"rendered":"<p class=\"preamble\">BioInvent, a clinical stage company focused on the development of novel, first-in-class immuno-modulatory antibodies for the treatment of cancer, has in March 2021 completed an equity financing of more than SEK 1,5 billion over a period of ten months.<\/p>\n<p>The equity finance consisted of a directed share issue in two tranches of a total of app. SEK 487 million in June 2020, one repair rights issue of SEK 139 million in July 2020, and a directed share issue in two tranches of a total of app. SEK 962 million, completing in March 2021.<\/p>\n<p>Proceeds will fund the expansion of clinical programs.\u00a0Investors in the directed share issues were a range of international and Swedish institutional investors, both existing and new.<\/p>\n<p>BioInvent was advised by Mannheimer Swartling.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioInvent, a clinical stage company focused on the development of novel, first-in-class immuno-modulatory antibodies for the treatment of cancer, has in March 2021 completed an\u2026<\/p>\n","protected":false},"author":9,"featured_media":17383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-18578","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":18578,"sv":18575},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/18578"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=18578"}],"version-history":[{"count":3,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/18578\/revisions"}],"predecessor-version":[{"id":18583,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/18578\/revisions\/18583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/17383"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=18578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=18578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=18578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}